Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
C 310.775 -1.03% -3.23
BGNE closed up 2.82 percent on Thursday, May 6, 2021, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical BGNE trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -1.03%
MACD Bearish Signal Line Cross Bearish -1.03%
Inside Day Range Contraction -1.03%
20 DMA Resistance Bearish 1.76%
Inside Day Range Contraction 1.76%
Down 3 Days in a Row Weakness 1.76%
Down 4 Days in a Row Weakness 1.76%
Fell Below 20 DMA Bearish 0.17%
Fell Below 50 DMA Bearish 0.17%
Expansion Pivot Sell Setup Bearish Swing Setup 0.17%
Older End-of-Day Signals for BGNE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 1 hour ago
20 DMA Resistance about 2 hours ago
20 DMA Support about 3 hours ago
60 Minute Opening Range Breakdown about 3 hours ago
Up 3% about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BeiGene, Ltd. Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Monoclonal Antibody Monoclonal Antibodies Lymphoma Oncogenes Protein Kinase Kras Humanized Antibody Ras Subfamily Bruton's Tyrosine Kinase Rp1

Is BGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 388.97
52 Week Low 155.16
Average Volume 256,593
200-Day Moving Average 288.81
50-Day Moving Average 320.08
20-Day Moving Average 315.54
10-Day Moving Average 328.41
Average True Range 15.15
ADX 17.45
+DI 21.05
-DI 27.65
Chandelier Exit (Long, 3 ATRs ) 314.40
Chandelier Exit (Short, 3 ATRs ) 334.75
Upper Bollinger Band 351.50
Lower Bollinger Band 279.58
Percent B (%b) 0.48
BandWidth 22.79
MACD Line 0.37
MACD Signal Line 0.73
MACD Histogram -0.3594
Fundamentals Value
Market Cap 28.55 Billion
Num Shares 90.9 Million
EPS -11.29
Price-to-Earnings (P/E) Ratio -27.82
Price-to-Sales 63.24
Price-to-Book 4.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 330.84
Resistance 3 (R3) 329.99 323.53 328.04
Resistance 2 (R2) 323.53 319.24 323.95 327.10
Resistance 1 (R1) 318.76 316.59 321.14 319.61 326.16
Pivot Point 312.30 312.30 313.49 312.72 312.30
Support 1 (S1) 307.53 308.01 309.92 308.39 301.84
Support 2 (S2) 301.07 305.36 301.49 300.90
Support 3 (S3) 296.30 301.07 299.96
Support 4 (S4) 297.16